Q-omics provides the consensus-scored OTOGL profile across patient tissues and cancer cell-line models. OTOGL expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OTOGL is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, OTOGL RNA expression shows 15,720 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where OTOGL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTOGL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTOGL survival associations across molecular data types. OTOGL RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTOGL RNA expression–survival associations across cancer types. High OTOGL expression shows unfavorable associations in BLCA, KIRP, UVM and STAD, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for OTOGL RNA expression.
This table summarizes OTOGL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for OTOGL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTOGL shows lower tumor expression in KICH, BLCA, KIRP and KIRC and higher tumor expression in LUAD and CHOL. The KICH box plot shows higher OTOGL RNA expression in normal versus tumor tissue (log2 FC = −0.719, t-test p < 0.001).
This table shows molecular features associated with OTOGL in patient tissues and cancer cell lines. In patient samples, OTOGL shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OTOGL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and STOMACH.
